IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
`
`Confirmation No.: 2363
`
`First Named Inventor:
`
`Hidekazu MASAKI
`
`Applicants:
`
`(1) Epsilon Molecular
`Engineering,Inc.;
`
`(2) The Kitasato Institute; and
`
`(3) Kao Corporation
`
`Art Unit: OPAP
`
`Appl. No.: 18/029,185
`
`35 U.S.C. § 371 Date: March 29, 2023
`
`US. Nat'l. Ph. of PCT/JP2021/036446
`
`LA. Filed: October 1, 2021
`
`For: SARS-COV-2-Binding Peptide
`
`Examiner: Docket Central
`
`Atty. Docket: 2537.2210006/MAC
`
`Second Supplemental Information Disclosure Statement
`Under37 C.F.R. § 1.97(b)
`
`Mail Stop Amendment
`
`Commissioner for Patents
`PO Box 1450
`Alexandria, VA 22313-1450
`
`Commissioner:
`
`Listed
`
`on
`
`accompanying
`
`IDS Forms
`
`PTO/SB/08A_
`
`equivalent
`
`and
`
`PTO/SB/08B equivalent are document
`
`that may be considered material
`
`to the
`
`patentability of this application as defined in 37 C.F.R. §1.56, and in compliance with
`
`the duty of disclosure requirements of 37 C.F.R. §§ 1.97 and 1.98.
`
`
`
`-2-
`
`Masakief al.
`Appl. No. 18/029,185
`
`Copies of document FP3 and NPL10-12 are being submitted. Documents
`
`FP3, NPL11 and NPL12 werecited in the partial supplementary European Search
`
`Report that was issued on September 27, 2024 for the counterpart European Patent
`
`Application No. 21 875 877.9, a copy of which is submitted herewith as document
`
`NPL10.
`
`Wherethe publication date of a listed document does not provide a month of
`
`publication, the year of publication of the listed documentis sufficiently earlier than
`
`the effective U.S. filing date and any foreign priority date so that the month of
`
`publication is not in issue.
`
`Applicants have listed the publication date on the attached IDS Forms based
`
`on information presently available to the undersigned.
`
`However,
`
`the listed
`
`publication dates should not be construed as an admission that the information was
`
`actually published on the date indicated.
`
`Applicants reserve the right to establish the patentability of the claimed
`
`invention over any of the information provided herewith, and/or to prove that this
`
`information may not be prior art, and/or to prove that this information may not be
`
`enabling for the teachings purportedly offered. This statement should not be
`
`construed as a representation that a search has been made, or that information more
`
`material to the examination of the present patent application does not exist. The
`
`Atty. Dkt. No. 2537.22 10006/MAC
`
`
`
`-3-
`
`Masakief al.
`Appl. No. 18/029,185
`
`Examiner is specifically requested not to rely solely on the material submitted
`
`herewith.
`
`This Information Disclosure Statement is being filed before the mailing date
`
`of a first Office action on the merits. No statement or fee is required.
`
`It
`
`is
`
`respectfully requested that the Examinerinitial and return a copy of the enclosed IDS
`
`Forms, and indicate in the official file wrapper of this patent application that the
`
`documents have been considered.
`
`The U.S. Patent and Trademark Office is hereby authorized to charge any fee
`
`deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.
`
`Respectfully submitted,
`
`STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
`
`/ Michele A. Cimbala /
`
`Michele A. Cimbala
`Attorney for Applicants
`Registration No. 33,851
`
`Date: November 26, 2024
`
`1101 K St, N.W.
`10" Floor
`Washington, D.C. 20005
`(202) 371-2600
`mcimbala@sternekessler.com
`
`23614330.1
`
`Atty. Dkt. No. 2537.22 10006/MAC
`
`
